Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

NCT03309592 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of eligible participants and failure to meeting study enrollment.

Conditions

Portopulmonary Hypertension
Pulmonary Hypertension
Cirrhosis, Liver

Interventions

DRUG: Ambrisentan Pill
DRUG: Tadalafil Pill

Sponsor

Ochsner Health System

Collaborators

[object Object]